Actively Recruiting
Effect of Drugs Changing Gut Bacteria on Immunotherapy Success in Advanced Non-Small Cell Lung Cancer
Led by University Hospital, Strasbourg, France · Updated on 2025-09-24
800
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Lung cancer is a leading cause of death in France, with most patients diagnosed at an advanced metastatic stage. Immunotherapy has improved survival for some metastatic non-small cell lung cancer NSCLC patients, but only about 20 to 30% respond to this treatment. Researchers are studying how drugs that alter the gut microbiota before starting immunotherapy may affect patient survival and treatment response in advanced NSCLC cases. The study observes patients with locally advanced stage III-C or metastatic stage IV NSCLC who receive immunotherapy. It focuses on the impact of medications taken within 90 days before the first immunotherapy dose that might change the gut bacteria composition. This observational study does not involve new treatments but evaluates how these drugs influence progression-free survival. Participants will be followed retrospectively, with researchers collecting data on their treatments, clinical outcomes, and biological markers. The main measure is progression-free survival starting from 90 days before immunotherapy initiation. The study aims to better understand how modifying gut bacteria through certain drugs affects immunotherapy effectiveness and patient survival over time.
CONDITIONS
Brief Title
Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
Research Team
C
Céline MASCAUX, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
